News
News
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma
06/04/2020 / 15:42 - GlobeNewswire - Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
05/28/2020 / 18:14 - GlobeNewswire - Genmab Announces Data to be Presented at the EHA25 Virtual Congress
05/14/2020 / 15:40 - GlobeNewswire - Genmab Announces Financial Results for the First Quarter of 2020
05/06/2020 / 17:01 - GlobeNewswire - Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma
05/01/2020 / 19:36 - GlobeNewswire - CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma
04/30/2020 / 20:55 - GlobeNewswire - Nkarta Therapeutics Appoints Two New Independent Directors
04/27/2020 / 14:30 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020
04/14/2020 / 12:35 - GlobeNewswire - Atopic Dermatitis Market Valuation to Approach US$ 19 Bn by 2027; Biologics Continue to Provide a Major Thrust, Finds a New Fact.MR Study
04/06/2020 / 15:00 - GlobeNewswire - Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
03/25/2020 / 15:00 - GlobeNewswire
Real-time